| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 90.354 | 24 | 0 | 849 | 21.393 | 1.396 | 680 | 0 | 0 | 25.340 |
| Total Income - EUR | 121.438 | 26 | 0 | 850 | 21.420 | 3.859 | 680 | 0 | 0 | 25.340 |
| Total Expenses - EUR | 122.527 | 1.183 | 3.998 | 5.403 | 37.614 | 9.123 | 605 | 28 | 503 | 25.664 |
| Gross Profit/Loss - EUR | -1.090 | -1.157 | -3.998 | -4.553 | -16.194 | -5.265 | 74 | -27 | -503 | -324 |
| Net Profit/Loss - EUR | -1.362 | -1.157 | -3.998 | -4.578 | -16.409 | -5.380 | 54 | -27 | -503 | -324 |
| Employees | 6 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
Check the financial reports for the company - Elpis Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 11.506 | 8.143 | 4.894 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 43.810 | 41.972 | 40.352 | 39.150 | 13.478 | 12.480 | 12.057 | 12.067 | 10.517 | 16.320 |
| Inventories | 0 | 0 | 169 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 36.128 | 34.434 | 33.953 | 35.225 | 12.008 | 10.660 | 10.456 | 10.488 | 10.457 | 10.550 |
| Cash | 7.681 | 7.539 | 6.230 | 3.925 | 1.470 | 1.821 | 1.601 | 1.578 | 60 | 5.771 |
| Shareholders Funds | 23.741 | 22.342 | 17.969 | 13.061 | -3.601 | -6.168 | -5.978 | -6.024 | -6.508 | -6.796 |
| Social Capital | 45 | 45 | 46 | 45 | 44 | 43 | 42 | 43 | 42 | 42 |
| Debts | 20.069 | 19.630 | 33.889 | 34.232 | 22.194 | 18.866 | 18.247 | 18.303 | 17.237 | 23.327 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4100 - 4100" | |||||||||
| CAEN Financial Year |
4520
|
|||||||||
Comments - Elpis Pharm Srl